StockNews.com initiated coverage on shares of Otonomy (NASDAQ:OTIC – Get Rating) in a research report sent to investors on Saturday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

Separately, Piper Sandler cut shares of Otonomy from an overweight rating to a neutral rating and cut their price objective for the company from $3.00 to $0.50 in a report on Thursday, October 13th.

Otonomy Price Performance

Shares of Otonomy stock opened at $0.07 on Friday. The firm has a fifty day moving average price of $0.11 and a 200 day moving average price of $0.66. Otonomy has a 1 year low of $0.06 and a 1 year high of $2.59. The stock has a market cap of $4.23 million, a PE ratio of -0.10 and a beta of 1.31.

Institutional Trading of Otonomy

Otonomy Company Profile

(Get Rating)

Otonomy, Inc, a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties.

Featured Articles

• Get a free copy of the StockNews.com research report on Otonomy (OTIC)
• 3 Industrial Stocks to Help Build Your 2023 Watchlist
• The Institutions Choose CarMax Over Carvana, Should You?
• Heatmap in Trading: How to Learn What Market Depth Hides
• Micron Technology Sees Chip Recovery by the End of 2023
• Three Healthcare Penny Stocks to Watch In The New Year

Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.